ETFs positioned on Zealand Pharma A/S

Name Weight AuM Varia. Jan 1. Investor
-0% 17 M€ 0.00% -
Logo Zealand Pharma A/S
Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2024, the Group had a portfolio of 6 products in clinical development (including 3 in phase III, 2 in phase II and 1 in phase I), and 2 products in preclinical development.
Employees
440
More about the company
Trader
Investor
Global
Quality
ESG MSCI
BBB
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
492.80DKK
Average target price
772.60DKK
Spread / Average Target
+56.78%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. ETFs Zealand Pharma A/S